Press coverage about Geron (NASDAQ:GERN) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Geron earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.0377925853606 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Geron (NASDAQ:GERN) opened at $2.01 on Thursday. Geron has a 12 month low of $1.74 and a 12 month high of $3.15.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.40 million. Geron had a negative return on equity of 25.14% and a negative net margin of 2,992.67%. The company’s revenue was down 96.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.02) earnings per share. analysts forecast that Geron will post -0.17 EPS for the current fiscal year.

Several analysts have issued reports on GERN shares. Zacks Investment Research upgraded Geron from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Tuesday, October 3rd. Stifel Nicolaus restated a “hold” rating and set a $2.50 price objective on shares of Geron in a report on Friday, November 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Geron in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Geron currently has an average rating of “Hold” and a consensus price target of $3.75.

WARNING: “Geron (GERN) Given News Sentiment Score of 0.08” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at

Geron Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Insider Buying and Selling by Quarter for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with Analyst Ratings Network's FREE daily email newsletter.